Schwartz, Jill L.

Jill L. Schwartz
Close

Contact Info

schwarjl@evms.edu

selected publications

2019

Vaginal microbiota and mucosal pharmacokinetics of tenofovir in healthy women using tenofovir and tenofovir/levonorgestrel vaginal rings. PLOS ONE. 14.
Full Text via DOI: 10.1371/journal.pone.0217229 PMID: 31107913
2019

The Effect of Hormonal Contraception on Cervicovaginal Mucosal End Points Associated with HIV Acquisition. AIDS RESEARCH AND HUMAN RETROVIRUSES. 35:1-12.
Full Text via DOI: 10.1089/aid.2018.0298 PMID: 30997816
2019

End-user preference for and choice of four vaginally delivered HIV prevention methods among young women in South Africa and Zimbabwe: the Quatro Clinical Crossover Study. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 22.
Full Text via DOI: 10.1002/jia2.25283 PMID: 31069957
2019

Comparison of self-reported female condom failure and biomarker-confirmed semen exposure. CONTRACEPTION. 100:406-412.
Full Text via DOI: 10.1016/j.contraception.2019.07.143 PMID: 31381878
2019

Effect of Hormonal Contraception on Pharmacokinetics of Vaginal Tenofovir in Healthy Women: Increased Tenofovir Diphosphate in Injectable Depot Medroxyprogesterone Acetate Users. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 80:79-88.
Full Text via DOI: 10.1097/QAI.0000000000001864 PMID: 30212395
2019

Efficacy is Not Everything: Eliciting Women's Preferences for a Vaginal HIV Prevention Product Using a Discrete-Choice Experiment. AIDS AND BEHAVIOR.
Full Text via DOI: 10.1007/s10461-019-02715-1 PMID: 31696371
2019

Integrated provision of topical pre-exposure prophylaxis in routine family planning services in South Africa: a non-inferiority randomized controlled trial. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 22.
Full Text via DOI: 10.1002/jia2.25381 PMID: 31507088
2019

Tenofovir Gel for Prevention of Herpes Simplex Virus Type 2 Acquisition: Findings From the VOICE Trial. JOURNAL OF INFECTIOUS DISEASES. 219:1940-1947.
Full Text via DOI: 10.1093/infdis/jiz045 PMID: 30753642
2018

Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial. LANCET INFECTIOUS DISEASES. 18:1241-1250.
2018

Anti-HIV Activity and Drug Concentrations in Tenofovir-based Products: Intravaginal Ring Versus Oral Tablet. AIDS RESEARCH AND HUMAN RETROVIRUSES. 343-343.
2018

Effect of Hormonal Contraception on Pharmacokinetics of Vaginal Tenofovir: Increased Tenofovir Diphosphate in Depot Medroxyprogesterone Acetate Users. AIDS RESEARCH AND HUMAN RETROVIRUSES. 342-342.
2018

HIV Prevention in Healthy Women: Safety and Pharmacokinetics of a Potential New Tenofovir Alafenamide Fumarate (TAF)-based Oral PrEP Regimen. AIDS RESEARCH AND HUMAN RETROVIRUSES. 56-56.
2018

Testing Objective Markers of Placebo Vaginal Product Adherence in the Field. AIDS RESEARCH AND HUMAN RETROVIRUSES. 26-26.
2018

Use of contraceptive depot medroxyprogesterone acetate is associated with impaired cervicovaginal mucosal integrity. JOURNAL OF CLINICAL INVESTIGATION. 128:4622-4638.
Full Text via DOI: 10.1172/JCI120583 PMID: 30222141
2018

Using Photovoice to Understand the Experience and Realities of Female Sex Workers in the Context of HIV Self-testing in Blantyre, Malawi. AIDS RESEARCH AND HUMAN RETROVIRUSES. 158-158.
2018

Vaginal Microbiota and Mucosal Pharmacokinetics of Tenofovir in Healthy Women Using Placebo, Tenofovir and Tenofovir/Levonorgestrel Vaginal Rings. AIDS RESEARCH AND HUMAN RETROVIRUSES. 295-295.
2018

FAME-04: A Phase 1 trial to assess the safety, acceptability, pharmacokinetics and pharmacodynamics of film and gel formulations of tenofovir. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 21.
Full Text via DOI: 10.1002/jia2.25156 PMID: 30101439
2018

Randomized, placebo controlled phase I trial of safety, pharmacokinetics, pharmacodynamics and acceptability of tenofovir and tenofovir plus levonorgestrel vaginal rings in women. PLOS ONE. 13.
Full Text via DOI: 10.1371/journal.pone.0199778 PMID: 29953547
2018

Pharmacokinetics and Pharmacodynamics of Tenofovir Reduced-Glycerin 1% Gel in the Rectal and Vaginal Compartments in Women: A Cross-Compartmental Study With Directly Observed Dosing. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 78:175-182.
Full Text via DOI: 10.1097/QAI.0000000000001655 PMID: 29767639
2018

Differences in Local and Systemic TFV PK Among Premenopausal Versus Postmenopausal Women Exposed to TFV 1% Vaginal Gel. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 78:82-92.
Full Text via DOI: 10.1097/QAI.0000000000001648 PMID: 29424790
2018

The Tablets, Ring, Injections as Options (TRIO) study: what young African women chose and used for future HIV and pregnancy prevention. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 21.
Full Text via DOI: 10.1002/jia2.25094 PMID: 29600595
2018

Acceptability of and Adherence to an Antiretroviral-Based Vaginal Microbicide among Pregnant Women in the United States. AIDS AND BEHAVIOR. 22:402-411.
Full Text via DOI: 10.1007/s10461-017-1811-9 PMID: 28550377
2018

Development and clinical assessment of new objective adherence markers for four microbicide delivery systems used in HIV prevention studies. CLINICAL AND TRANSLATIONAL MEDICINE. 7.
Full Text via DOI: 10.1186/s40169-018-0213-6 PMID: 30402770
2018

Tenofovir 1% vaginal gel for prevention of HIV-1 infection in women in South Africa (FACTS-001): a phase 3, randomised, double-blind, placebo-controlled trial. LANCET INFECTIOUS DISEASES. 18:1241-1250.
Full Text via DOI: 10.1016/S1473-3099(18)30428-6 PMID: 30507409
2017

A phase I randomized postcoital testing and safety study of the Caya diaphragm used with 3% Nonoxynol-9 gel, ContraGel or no gel. CONTRACEPTION. 96:124-130.
Full Text via DOI: 10.1016/j.contraception.2017.05.016 PMID: 28606382
2017

Comparison of Mucosal Markers of Human Immunodeficiency Virus Susceptibility in Healthy Premenopausal Versus Postmenopausal Women. AIDS RESEARCH AND HUMAN RETROVIRUSES. 33:807-819.
Full Text via DOI: 10.1089/aid.2016.0320 PMID: 28398069
2017

MTN-017: A Rectal Phase 2 Extended Safety and Acceptability Study of Tenofovir Reduced-Glycerin 1% Gel. CLINICAL INFECTIOUS DISEASES. 64:614-620.
Full Text via DOI: 10.1093/cid/ciw832 PMID: 27986684
2016

Clinical Assessment of New Objective Measures of Adherence for Four Placebo Vaginal Dosage Platforms. AIDS RESEARCH AND HUMAN RETROVIRUSES. 95-95.
2016

Clinical Performance, Acceptability, and Optimization of Fast-dissolve Vaginal Inserts Designed for HIV-prevention: Results from Two Clinical Studies. AIDS RESEARCH AND HUMAN RETROVIRUSES. 53-53.
2016

Correlation of Residual Microbicide Levels with Objective Biomarker Analysis to Determine Adherence in a Large Phase III HIV Prevention Trial. AIDS RESEARCH AND HUMAN RETROVIRUSES. 387-387.
2016

Development and Proof-of-Concept Clinical Evaluation of a Freeze-dried Topical Microbicide Insert for On-demand HIV Prevention. AIDS RESEARCH AND HUMAN RETROVIRUSES. 69-69.
2016

Pharmacokinetics/Pharmacodynamics of Tenofovir and Tenofovir Plus Levonorgestrel Vaginal Rings in Women. AIDS RESEARCH AND HUMAN RETROVIRUSES. 389-389.
2016

The Role of Vitamin D on Genital Mucosal Immunity and Markers of HIV Susceptibility in Women. AIDS RESEARCH AND HUMAN RETROVIRUSES. 320-320.
2016

A randomized safety and pharmacokinetic trial of daily tenofovir 1% gel in term and near-term pregnancy. JOURNAL OF THE INTERNATIONAL AIDS SOCIETY. 19.
Full Text via DOI: 10.7448/IAS.19.1.20990 PMID: 27658440
2016

Comparison of Follicular and Luteal Phase Mucosal Markers of HIV Susceptibility in Healthy Women. AIDS RESEARCH AND HUMAN RETROVIRUSES. 32:547-560.
Full Text via DOI: 10.1089/aid.2015.0264 PMID: 26750085
2016

Detectable Tenofovir Levels in Breast-Feeding Infants of Mothers Exposed to Topical Tenofovir. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 60:5616-5619.
Full Text via DOI: 10.1128/AAC.00645-16 PMID: 27401570
2016

Project Gel a Randomized Rectal Microbicide Safety and Acceptability Study in Young Men and Transgender Women. PLOS ONE. 11.
Full Text via DOI: 10.1371/journal.pone.0158310 PMID: 27362788
2015

A Pilot Study Measuring the Distribution and Permeability of a Vaginal HIV Microbicide Gel Vehicle Using Magnetic Resonance Imaging, Single Photon Emission Computed Tomography/Computed Tomography, and a Radiolabeled Small Molecule. AIDS RESEARCH AND HUMAN RETROVIRUSES. 31:1109-1115.
Full Text via DOI: 10.1089/aid.2015.0054 PMID: 26077739
2015

Bacterial Vaginosis and Subclinical Markers of Genital Tract Inflammation and Mucosal Immunity. AIDS RESEARCH AND HUMAN RETROVIRUSES. 31:1139-1152.
Full Text via DOI: 10.1089/aid.2015.0006 PMID: 26204200
2015

Contraceptive Efficacy, Safety, Fit, and Acceptability of a Single-Size Diaphragm Developed With End-User Input. OBSTETRICS AND GYNECOLOGY. 125:895-903.
Full Text via DOI: 10.1097/AOG.0000000000000721 PMID: 25751199
2015

Tenofovir-Based Preexposure Prophylaxis for HIV Infection among African Women. NEW ENGLAND JOURNAL OF MEDICINE. 372:509-518.
Full Text via DOI: 10.1056/NEJMoa1402269 PMID: 25651245
2014

Comparison of Visual and Ultraviolet Light Inspection Versus DNA/Protein Biomarkers to Assess Product Adherence With Vaginal Microbicide Applicators. SEXUALLY TRANSMITTED DISEASES. 41:739-746.
Full Text via DOI: 10.1097/OLQ.0000000000000209 PMID: 25581811
2014

Assessment of the Vaginal Residence Time of Biomarkers of Semen Exposure. AIDS RESEARCH AND HUMAN RETROVIRUSES. A172-A172.
2014

Effect of Bacterial Vaginosis on Markers of Genital Tract Inflammation and Mucosal Immunity: Mechanisms for Susceptibility to HIV Infection. AIDS RESEARCH AND HUMAN RETROVIRUSES. A30-A30.
2014

Multicompartmental Pharmacokinetics of Tenofovir 1% Gel Using the BAT 24 Regimen Versus Daily and Single Pericoital Dosing. AIDS RESEARCH AND HUMAN RETROVIRUSES. A37-A37.
2014

Obstetric and Infant Outcomes Following Planned Maternal Third Trimester Exposure to Tenofovir 1% Vaginal Gel. AIDS RESEARCH AND HUMAN RETROVIRUSES. A267-A268.
2014

Population Pharmacokinetic Model of Vaginal Tenofovir 1% Gel in the Cervicovaginal Fluid. AIDS RESEARCH AND HUMAN RETROVIRUSES. A38-A38.
2014

Tenofovir Gel Acceptability and Adherence among Pregnant Women in the United States. AIDS RESEARCH AND HUMAN RETROVIRUSES. A282-A283.
2014

Effect of oral administration of a continuous 18 day regimen of meloxicam on ovulation: experience of a randomized controlled trial. CONTRACEPTION. 90:168-173.
Full Text via DOI: 10.1016/j.contraception.2014.04.011 PMID: 24909636
2014

Effect of lubricants and a vaginal spermicide gel on the detection of prostate specific antigen, a biomarker of semen exposure, using a quantitative (Abbott ARCHITECT) assay. CONTRACEPTION. 89:134-138.
Full Text via DOI: 10.1016/j.contraception.2013.09.016 PMID: 24314911
2013

Toward Early Safety Alert Endpoints: Exploring Biomarkers Suggestive of Microbicide Failure. AIDS RESEARCH AND HUMAN RETROVIRUSES. 29:1475-1486.
Full Text via DOI: 10.1089/aid.2012.0345 PMID: 23885658
2013

Medroxyprogesterone acetate and estradiol cypionate injectable suspension (Cyclofem) monthly contraceptive injection: steady-state pharmacokinetics. CONTRACEPTION. 87:738-743.
Full Text via DOI: 10.1016/j.contraception.2012.11.010 PMID: 23265980
2012

Dyeing to Know: The Use of Vaginal Applicator Staining and Other Techniques to Assess Adherence to Product Use in Microbicide Trials. SEXUALLY TRANSMITTED DISEASES. 713-715.
Full Text via DOI: 10.1097/OLQ.0b013e318264f6b0 PMID: 22902668
2012

The Safety, Persistence, and Acceptability of an Antiretroviral Microbicide Candidate UC781. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 60:337-343.
Full Text via DOI: 10.1097/QAI.0b013e3182575914 PMID: 22495787
2012

Colposcopy: Still Useful in Microbicide Safety Trials?. SEXUALLY TRANSMITTED DISEASES. 39:465-469.
Full Text via DOI: 10.1097/OLQ.0b013e3182500f33 PMID: 22592833
2011

A Multi-Compartment, Single and Multiple Dose Pharmacokinetic Study of the Vaginal Candidate Microbicide 1% Tenofovir Gel. PLOS ONE. 6.
Full Text via DOI: 10.1371/journal.pone.0025974 PMID: 22039430
2011

Baseline variation and associations between subject characteristics and five cytokine biomarkers of vaginal safety among healthy non-pregnant women in microbicide trials. CYTOKINE. 55:134-140.
Full Text via DOI: 10.1016/j.cyto.2011.03.016 PMID: 21530305
2011

Reddy female condom: functional performance of a 90-mm shaft length in two clinical studies. CONTRACEPTION. 83:466-471.
Full Text via DOI: 10.1016/j.contraception.2010.09.015 PMID: 21477691
2010

Suppression of Follicular Rupture With Meloxicam, A Cyclooxygenase-2 Inhibitor: Potential for Emergency Contraception EDITORIAL COMMENT. OBSTETRICAL & GYNECOLOGICAL SURVEY. 314-316.
Full Text via DOI: 10.1097/OGX.0b013e3181e39ca0
2010

Suppression of follicular rupture with meloxicam, a cyclooxygenase-2 inhibitor: potential for emergency contraception. HUMAN REPRODUCTION. 25:368-373.
Full Text via DOI: 10.1093/humrep/dep392 PMID: 19933235
2009

Safety evaluation of 1% tenofovir gel in healthy men. INTERNATIONAL JOURNAL OF STD & AIDS. 20:384-386.
Full Text via DOI: 10.1258/ijsa.2008.008309 PMID: 19451321
2009

Critical next steps for female condom research - report from a workshop. CONTRACEPTION. 339-344.
Full Text via DOI: 10.1016/j.contraception.2008.12.005 PMID: 19341844
2008

Comparative crossover study of the PATH Woman's Condom and the FC Female Condom (R). CONTRACEPTION. 78:465-473.
Full Text via DOI: 10.1016/j.contraception.2008.07.020 PMID: 19014792
2008

Six-Day Randomized Safety Trial of Intravaginal Lime Juice. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 49:243-250.
2008

SILCS diaphragm: postcoital testing of a new single-size contraceptive device. CONTRACEPTION. 78:237-244.
Full Text via DOI: 10.1016/j.contraception.2008.04.118 PMID: 18692615
2008

A Randomized six-day safety study of an antiretroviral microbicide candidate UC781, a non-nucleoside reverse transcriptase inhibitor. SEXUALLY TRANSMITTED DISEASES. 35:414-419.
Full Text via DOI: 10.1097/OLQ.0b013e318162c4d8 PMID: 18362865
2008

Noncomparative contraceptive efficacy of cellulose sulfate gel. OBSTETRICS AND GYNECOLOGY. 111:739-746.
2007

Fourteen-day safety and acceptability study of the universal placebo gel. CONTRACEPTION. 75:136-141.
Full Text via DOI: 10.1016/j.contraception.2006.09.003 PMID: 17241844
2006

Fourteen-day safety and acceptability study of 6% cellulose sulfate gel: a randomized double-blind Phase I safety study. CONTRACEPTION. 74:133-140.
Full Text via DOI: 10.1016/j.contraception.2006.02.008 PMID: 16860051
2006

FemCap (TM) with removal strap: ease of removal, safety and acceptability. CONTRACEPTION. 73:59-64.
Full Text via DOI: 10.1016/j.contraception.2005.06.074 PMID: 16371297
2005

In vitro and in vivo characterization of a potential universal placebo designed for use in vaginal microbicide clinical trials. AIDS RESEARCH AND HUMAN RETROVIRUSES. 21:845-853.
2005

Male tolerance of ACIDFORM gel. CONTRACEPTION. 71:443-446.
Full Text via DOI: 10.1016/j.contraception.2004.11.008 PMID: 15914134

full name

Jill L. Schwartz

visualizations

Publications in VIVO

Co-author Network

research areas